




PHARMACEUTICAL 2021

Teligent Inc.
Rank 356 of 402





PHARMACEUTICAL 2021

Teligent Inc.
Rank 356 of 402

The relative strengths and weaknesses of Teligent Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Teligent Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Teligent Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 197% points.

The company's Economic Capital Ratio, given in the ranking table, is -218%, being 265% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	44,291
Cost of Goods Sold	49,031
Intangible Assets	23,465
Liabilities, Current	23,121
Liabilities, Non-Current	4,914
Other Assets	20,032
Other Compr. Net Income	264
Other Expenses	112,654
Other Liabilities	169,905
Other Net Income	25,690
Other Revenues	48,658
Property and Equipment	0
Research and Development	7,674
Selling, General and Administrative Expense	27,011

Output Variable	Value in 1000 USD
Assets	87,788
Liabilities	197,940
Expenses	196,370
Revenues	48,658
Stockholders Equity	-110,152
Net Income	-122,022
Comprehensive Net Income	-121,890
Economic Capital Ratio	-218%